Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Sunesis starts dosing in Phase Ib/II trial of SNS-062 for B-cell malignancies

Go Top